New cancer drug LBL-033 tested in 26 patients – safety first
NCT ID NCT05779163
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new drug called LBL-033 in 26 adults with advanced malignant tumors that had not responded to other treatments. The main goals were to find a safe dose and check for serious side effects. Researchers also looked at how the drug moves through the body and whether it can help control tumor growth.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANT TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fujian Cancer Hospital
Fuzhou, Fujian, 350014, China
-
Henan Cancer Hospital
Zhengzhou, Henan, 450003, China
-
Liaoning Cancer Hospital & Institute
Shenyang, Liaoning, 110801, China
-
Obstetrics & Gynecology Hospital of Fudan University
Shanghai, Shanghai Municipality, 200011, China
-
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, 510062, China
-
West China Second University Hospital,Sichuan University
Chengdu, Sichuan, 610044, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.